Household Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 in the United States.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
05 10 2021
Historique:
received: 04 07 2020
pubmed: 14 11 2020
medline: 12 10 2021
entrez: 13 11 2020
Statut: ppublish

Résumé

The evidence base for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is nascent. We sought to characterize SARS-CoV-2 transmission within US households and estimate the household secondary infection rate (SIR) to inform strategies to reduce transmission. We recruited patients with laboratory-confirmed SARS-CoV-2 infection and their household contacts in Utah and Wisconsin during 22 March 2020-25 April 2020. We interviewed patients and all household contacts to obtain demographics and medical histories. At the initial household visit, 14 days later, and when a household contact became newly symptomatic, we collected respiratory swabs from patients and household contacts for testing by SARS-CoV-2 real-time reverse-transcription polymerase chain reaction (rRT-PCR) and sera for SARS-CoV-2 antibodies testing by enzyme-linked immunosorbent assay (ELISA). We estimated SIR and odds ratios (ORs) to assess risk factors for secondary infection, defined by a positive rRT-PCR or ELISA test. Thirty-two (55%) of 58 households secondary infection among household contacts. The SIR was 29% (n = 55/188; 95% confidence interval [CI], 23%-36%) overall, 42% among children (aged <18 years) of the COVID-19 patient and 33% among spouses/partners. Household contacts to COVID-19 patients with immunocompromised conditions and household contacts who themselves had diabetes mellitus had increased odds of infection with ORs 15.9 (95% CI, 2.4-106.9) and 7.1 (95% CI: 1.2-42.5), respectively. We found substantial evidence of secondary infections among household contacts. People with COVID-19, particularly those with immunocompromising conditions or those with household contacts with diabetes, should take care to promptly self-isolate to prevent household transmission.

Sections du résumé

BACKGROUND
The evidence base for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is nascent. We sought to characterize SARS-CoV-2 transmission within US households and estimate the household secondary infection rate (SIR) to inform strategies to reduce transmission.
METHODS
We recruited patients with laboratory-confirmed SARS-CoV-2 infection and their household contacts in Utah and Wisconsin during 22 March 2020-25 April 2020. We interviewed patients and all household contacts to obtain demographics and medical histories. At the initial household visit, 14 days later, and when a household contact became newly symptomatic, we collected respiratory swabs from patients and household contacts for testing by SARS-CoV-2 real-time reverse-transcription polymerase chain reaction (rRT-PCR) and sera for SARS-CoV-2 antibodies testing by enzyme-linked immunosorbent assay (ELISA). We estimated SIR and odds ratios (ORs) to assess risk factors for secondary infection, defined by a positive rRT-PCR or ELISA test.
RESULTS
Thirty-two (55%) of 58 households secondary infection among household contacts. The SIR was 29% (n = 55/188; 95% confidence interval [CI], 23%-36%) overall, 42% among children (aged <18 years) of the COVID-19 patient and 33% among spouses/partners. Household contacts to COVID-19 patients with immunocompromised conditions and household contacts who themselves had diabetes mellitus had increased odds of infection with ORs 15.9 (95% CI, 2.4-106.9) and 7.1 (95% CI: 1.2-42.5), respectively.
CONCLUSIONS
We found substantial evidence of secondary infections among household contacts. People with COVID-19, particularly those with immunocompromising conditions or those with household contacts with diabetes, should take care to promptly self-isolate to prevent household transmission.

Identifiants

pubmed: 33185244
pii: 5893024
doi: 10.1093/cid/ciaa1166
pmc: PMC7454394
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1805-1813

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Auteurs

Nathaniel M Lewis (NM)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Utah Department of Health, Salt Lake City, Utah, USA.

Victoria T Chu (VT)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Dongni Ye (D)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Erin E Conners (EE)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Radhika Gharpure (R)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Rebecca L Laws (RL)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Hannah E Reses (HE)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Brandi D Freeman (BD)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Mark Fajans (M)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Elizabeth M Rabold (EM)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Patrick Dawson (P)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sean Buono (S)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sherry Yin (S)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Daniel Owusu (D)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ashutosh Wadhwa (A)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Mary Pomeroy (M)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Anna Yousaf (A)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Eric Pevzner (E)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Henry Njuguna (H)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Katherine A Battey (KA)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Cuc H Tran (CH)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Victoria L Fields (VL)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Phillip Salvatore (P)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Michelle O'Hegarty (M)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Jeni Vuong (J)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Rebecca Chancey (R)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Christopher Gregory (C)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Michelle Banks (M)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Jared R Rispens (JR)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Elizabeth Dietrich (E)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Perrine Marcenac (P)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Almea M Matanock (AM)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lindsey Duca (L)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Allison Binder (A)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Garrett Fox (G)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sandra Lester (S)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lisa Mills (L)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Susan I Gerber (SI)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

John Watson (J)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Amy Schumacher (A)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lucia Pawloski (L)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Natalie J Thornburg (NJ)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Aron J Hall (AJ)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Tair Kiphibane (T)

Salt Lake County Health Department, Salt Lake City, Utah, USA.

Sarah Willardson (S)

Davis County Health Department, Clearfield, Utah, USA.

Kim Christensen (K)

Utah Department of Health, Salt Lake City, Utah, USA.

Lindsey Page (L)

City of Milwaukee Health Department, Milwaukee, Wisconsin, USA.

Sanjib Bhattacharyya (S)

City of Milwaukee Health Department, Milwaukee, Wisconsin, USA.

Trivikram Dasu (T)

City of Milwaukee Health Department, Milwaukee, Wisconsin, USA.

Ann Christiansen (A)

North Shore Health Department, Milwaukee, Wisconsin, USA.

Ian W Pray (IW)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Wisconsin Department of Health Services, Madison, Wisconsin, USA.

Ryan P Westergaard (RP)

Wisconsin Department of Health Services, Madison, Wisconsin, USA.

Angela C Dunn (AC)

Utah Department of Health, Salt Lake City, Utah, USA.

Jacqueline E Tate (JE)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Scott A Nabity (SA)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Hannah L Kirking (HL)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH